Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome (FCS)


News provided by

Akcea

11 Jul, 2017, 08:47 GMT

Share this article

Share toX

Share this article

Share toX

CAMBRIDGE, Massachusetts, July 11, 2017 /PRNewswire/ --

IN-FOCUS[1] data presented at HEART UK explore the severe impact of rare genetic disease for which there is currently no treatment  

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), has presented IN-FOCUS: new data on Familial Chylomicronaemia Syndrome (FCS) revealing how psychosocial and cognitive symptoms translate into reduced quality of life and an impaired ability to work for patients. While acute symptoms of this disorder are well-documented, until now there has only been minimal research into the holistic burden of FCS and its far-reaching impact on quality of life.[1]

FCS affects approximately one to two people in a million in Europe.[2] It is characterised by a dysfunction of lipoprotein lipase (LPL), an enzyme that breaks down chylomicrons: large lipoprotein particles that carry triglycerides in the blood shortly after the ingestion of fat.[3] As a result, people with FCS have very high levels of triglycerides in their blood, which can cause it to appear milky in colour.[3] FCS can cause severe abdominal pain and has the potential to lead to acute pancreatitis which can be fatal or cause permanent pancreatic damage.[3] There is currently no treatment available for FCS and sufferers must resort to adopting severely restricted diets.[4]

The data reveal that the emotional burden of FCS is substantial. 64% of people living with FCS consider the disease to have adversely affected their lives over the past 12 months;[1] 57% feel that their disease is a burden to those around them.[1] 64% reported that the disease had affected their stress/anxiety levels, 54% said it affected their mental ability, and 50% said it affected their quality of sleep.[1] Patients reported feeling 'sad, down, blue or depressed' about their condition on a weekly basis.[1] Anxiety, fear, or worry about having to plan what or how much they could eat also troubled them on a monthly basis.[1]

The study highlighted cognitive symptoms of FCS that had previously been relatively undocumented.[1] Participants in the study reported that they experienced impaired judgements as frequently as every day and difficulty hearing as often as twice a week.[1] Severe 'brain fog', forgetfulness and recent memory loss were also reported.[1]

"FCS impacts most areas of the life of someone who has it and those close to them. It affects everything from what they can eat to their relationships with their friends and family, their employment and their sense of self-worth," says Jill Prawer, Chair of the LPLD alliance. "FCS is often misunderstood and misdiagnosed, and we are delighted that the impact of the disorder beyond immediate acute symptoms is starting to be investigated."

FCS sufferers find themselves frequently having to access both primary and secondary healthcare services.[1] 86% of patients in the study visited their GP for routine appointments on average 10 times in twelve months and 64% visited their GP for urgent care an average of three times.[1] 71% visited a hospital doctor an average of three times in twelve months, 50% were hospitalised twice on average, for an average of four nights.[1]

The study also reveals that 57.1% of FCS patients feel that the disease significantly interferes with their work and employment, and many feel constant uncertainty about having an attack of pain or acute pancreatitis multiple times per day.[1] 43% of patients had to take an average of 11 days off work in the last twelve months due to their FCS.[1]Outside of work, 58% said that it had influenced their decision on whether or not to have children.[1]

IN-FOCUS was a self-reported, online, anonymous quantitative research study conducted in those diagnosed with FCS.[1]These results reflect an interim analysis of responses from European patients. Data were presented at the HEART UK 31st Annual Medical & Scientific Congress between 5-7 July 2017.[1]

About FCS[3]

Familial Chylomicronaemia Syndrome (FCS) is a rare genetic lipid disorder characterised by the build up of chylomicrons (chylomicronaemia), large lipoprotein particles that carry triglycerides in the blood shortly after the ingestion of fat. People with FCS cannot break down chylomicrons, causing them to have very high levels of triglycerides and blood than can appear milky in colour (lipemic). People with FCS live at risk of severe recurrent abdominal pain and potentially acute pancreatitis, long-term complications from pancreatic damage, and symptoms that can interfere with daily life. People with FCS are normally required to sustain a low fat diet of less than 20g per day.

FCS is caused by a dysfunction of Lipoprotein lipase (LPL), an enzyme that works to help break down chylomicrons in the body. The genetic mutations for FCS are inherited as an autosomal recessive trait. It is estimated to affect 1-2 in every 1 million people in the EU.

About IN-FOCUS[1]

IN-FOCUS (Interim Results of the Investigation of Findings and Observations Captured in Burden of Illness Survey in Patients with FCS) aimed to establish the burden of disease in patients with FCS.

IN-FOCUS was a self-reported, online, anonymous quantitative research study, conducted with patients with FCS. The study utilised a web survey that was approximately 45 min in duration. All research materials were approved by relevant country-level ethics committee. Research questions included asking patients with FCS about their diagnosis, initial experiences with FCS, symptoms, comorbidities, FCS management and impact of FCS on different dimensions of their lives.

Across Europe, the data were collected from 14 adults patients (7 male, 7 female) from 5 countries: UK (n=8), Germany (n=2), Sweden (n=2), Spain (n=1) and Portugal (n=1) - approximately 10% of the worldwide survey population. The mean age was 36.1 years (range 19-68). The mean age at diagnosis was 9.4 years (range 1-18). 100% of patients had triglycerides .8.4mmol/l (750mg/dL) at diagnosis.

ABOUT AKCEA THERAPEUTICS  

Akcea Therapeutics is a development and commercialisation company focused on transforming the lives of patients with serious cardiometabolic lipid disorders. Akcea has a robust portfolio of development-stage drugs covering multiple targets and diseases using advanced RNA-targeted antisense therapeutics.

Akcea's drug pipeline includes three novel antisense drugs designed to address a number of lipid risk factors, including ApoC-III, triglycerides, Lp(a), and LDL-cholesterol. Akcea is continuing to assemble the global infrastructure to develop and commercialise the drugs in its pipeline. Akcea is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. and is located in Cambridge, Massachusetts.

References

1. Davidson M et al. Interim Results of the Investigation of Findings and Observations Captured in Burden of Illness Survey in Patients with FCS (IN-FOCUS) Study: European Respondents. Presented at the HEART UK 31st Annual Medical & Scientific Conference, University of Warwick, Coventry, UK. 5-7 July 2017.

2. European Medicines Agency. Committee for Orphan Medicinal Products EMA/COMP/14515/2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2014/03/WC500162743.pdf [Accessed July 2017]

3. Brunzell JD. Familial lipoprotein lipase deficiency. GeneReviews 2011.

4. NORD. Familial Partial Lipodystrophy. Available at: https://rarediseases.org/rare-diseases/familial-partial-lipodystrophy/ [https://rarediseases.org/rare-diseases/familial-partial-lipodystrophy] Accessed July 2017

AKC-014-020
July 2017

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.